Skip to main content
NATCOPHARM · Health Care · 2026-08-21

Natco Pharma Ltd

Stage 4 · wk 3In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹882.4
+0.56% today
₹15,805 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Visit company website →
P/E (TTM)
13.5
Forward 29.4
Earnings Growth (YoY)
+13.9%
Revenue +36.3%
Dividend Yield
0.55%
P/B 2.4
vs 52W High
-26.8%
₹790.2 lo₹1,206 hi
26.8% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-6.5%
200 DMA: ₹943.3 · rising
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.63x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
MA20 rolling over · -2.7% vs MA50 -5.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 22w
S2 41w
S4 15w
S1 15w
S2 14w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 22w → S3 11w → S2 41w → S3 9w → S2 2w → S3 4w → S4 15w → S1 15w → S4 13w → S1 4w → S2 6w → S3 1w → S4 2w → S3 1w → S2 14w → S3 7w → S4 3w current
Total tracked: 168 weeks across 17 stage runs.
1M
-3.9%
3M
-24.6%
6M
+0.3%
YTD
-1.3%
1Y
-1.8%
Scan Membership
Breakout Watch
Latest: 2026-03-10
4 appearances in last 60 days. First seen: 2024-01-18.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S4
Wk 3 · Vol x
2026-08-20S4
Wk 3 · Vol x
2026-08-19S4
Wk 3 · Vol x
2026-08-18S4
Wk 3 · Vol x
2026-08-17S4
Wk 2 · Vol x
2026-08-14S4
Wk 2 · Vol x
2026-08-13S4
Wk 2 · Vol x
2026-08-12S4
Wk 2 · Vol x
2026-08-11S4
Wk 2 · Vol x
2026-08-10S4
Wk 1 · Vol x
2026-08-07S4
Wk 1 · Vol x
2026-08-06S4
Wk 1 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹920.4
200 DMA
₹943.3
52W High
₹1,206
52W Low
₹790.2
5D Low
₹877.5
Resistance levels (recent highs)
20d High
₹951.7
60d High
₹1,015.9
120d High
₹1,206
250d High
₹1,206
Next resistance
+7.9%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.